1. Home
  2. TOL vs GH Comparison

TOL vs GH Comparison

Compare TOL & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toll Brothers Inc.

TOL

Toll Brothers Inc.

HOLD

Current Price

$146.82

Market Cap

15.7B

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$90.50

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOL
GH
Founded
1967
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.7B
13.3B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
TOL
GH
Price
$146.82
$90.50
Analyst Decision
Buy
Strong Buy
Analyst Count
17
19
Target Price
$164.44
$119.79
AVG Volume (30 Days)
1.1M
2.1M
Earning Date
05-19-2026
05-07-2026
Dividend Yield
0.68%
N/A
EPS Growth
N/A
6.74
EPS
2.19
N/A
Revenue
$7,143,258,000.00
$982,021,000.00
Revenue This Year
N/A
$33.30
Revenue Next Year
$6.01
$28.27
P/E Ratio
$66.95
N/A
Revenue Growth
N/A
32.88
52 Week Low
$93.52
$36.36
52 Week High
$168.36
$120.74

Technical Indicators

Market Signals
Indicator
TOL
GH
Relative Strength Index (RSI) 59.52 53.42
Support Level $128.61 $89.32
Resistance Level $150.45 $101.77
Average True Range (ATR) 3.81 5.54
MACD 1.58 0.65
Stochastic Oscillator 85.13 69.78

Price Performance

Historical Comparison
TOL
GH

About TOL Toll Brothers Inc.

Toll Brothers Inc is the luxury homebuilder in the USA, operating in over 60 markets across 24 states. The Fort Washington, Pennsylvania-headquartered homebuilder caters to affluent first-time, move-up, active-adult, and second-homebuyers. Toll Brothers has shifted in recent years to a greater mix of speculative, or "quick move-in" homes. The homebuilder has also expanded its price points, with a greater emphasis on "affordable luxury. Traditional homebuilding accounts for the majority of Toll Brothers' earnings, but the firm also offers ancillary mortgage, title, insurance, and other services.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: